NEW YORK (GenomeWeb) – Cenix BioScience this week announced it has signed an agreement to provide target-validation services to BASF company Metanomics.
NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.
Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.
Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.
The company has added respiratory and inflammation to an RNAi screening program that began with oncology.
The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.
The company will use RNAi technologies for cell-based screens for cancer drugs.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.